A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine

The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.

开始日期2014-04-01

申办/合作机构

Eleison Pharmaceuticals, Inc.

NCT00441467

/ Completed临床2期

An Open-Label Phase 2 Study of the Efficacy and Safety of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma

Primary Objective:
1. To evaluate the efficacy of glufosfamide in subjects with advanced soft tissue sarcoma as measured by objective response rate
Secondary Objectives:
1. To evaluate the efficacy of glufosfamide in subjects with advanced soft tissue sarcoma as measured by duration of response, progression-free survival and overall survival
2. To evaluate the safety of glufosfamide in subjects with advanced soft tissue sarcoma
Exploratory Objectives:
1. To evaluate the biological effect of glufosfamide on the metabolic profile in subjects with advanced soft tissue sarcomas, as determined by FDG-PET
2. To correlate efficacy endpoints with expression of tumor-associated glucose transporter proteins

开始日期2007-03-01

申办/合作机构

Eleison Pharmaceuticals, Inc.

[+1]

NCT00435578

/ Terminated临床2期

An Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of Glufosfamide in the Treatment of Patients With Recurrent Sensitive Small Cell Lung Carcinoma

The primary objectives of this study are:
1. To evaluate the efficacy of glufosfamide in subjects with extensive recurrent sensitive small cell lung cancer (SCLC) as measured by objective response rate
2. To evaluate the safety of glufosfamide in subjects with extensive recurrent sensitive SCLC
The secondary objectives are:
1. To evaluate the efficacy of glufosfamide in subjects with extensive recurrent sensitive SCLC as measured by duration of response, progression-free survival and overall survival
2. To evaluate the pharmacokinetics of glufosfamide and isophosphoramide mustard (IPM)
The exploratory objectives of this trial are:
1. To evaluate the effect of glufosfamide on lung cancer symptoms
2. To evaluate the role of tumor cell glucose transporter expression on the efficacy of glufosfamide

开始日期2007-02-01

申办/合作机构

Threshold Pharmaceuticals, Inc.

100 项与葡膦酰胺相关的临床结果

登录后查看更多信息

100 项与葡膦酰胺相关的转化医学

登录后查看更多信息

100 项与葡膦酰胺相关的专利（医药）

登录后查看更多信息

项与葡膦酰胺相关的文献（医药）

2024-03-31·Aging

Identification and validation of ferroptosis-related gene SLC2A1 as a novel prognostic biomarker in AKI

Article

作者: Wang, Huaying ; Wu, Yonggui ; Li, Yuanyuan ; Liu, Xinran

BACKGROUND:

Emerging evidence reveals the key role of ferroptosis in the pathophysiological process of acute kidney injury (AKI). Our study aimed to investigate the potential ferroptosis-related gene in AKI through bioinformatics and experimental validation.

METHODS:

The AKI single-cell sequencing dataset was retrieved from the GEO database and ferroptosis-related genes were extracted from the GENECARD website. The potential differentially expressed ferroptosis-related genes of AKI were selected. Functional enrichment analysis was performed. Machine learning algorithms were used to identify key ferroptosis-related genes associated with AKI. A multi-factor Cox regression analysis was used to construct a risk score model. The accuracy of the risk score model was validated using receiver operating characteristic (ROC) curve analysis. We extensively explored the immune landscape of AKI using CIBERSORT tool. Finally, expressions of ferroptosis DEGs were validated in vivo and in vitro by Western blot, ICH and transfection experiments.

RESULTS:

Three hub genes (BAP1, MDM4, SLC2A1) were identified and validated by constructing drug regulatory network and subsequent screening using experimentally determined interactions. The risk mode showed the low-risk group had significantly better prognosis compared to high-risk group. The risk score was independently associated with overall survival. The ROC curve analysis showed that the prognosis model had good predictive ability. Additionally, CIBERSORT immune infiltration analysis suggest that the hub gene may influence cell recruitment and infiltration in AKI. Validation experiments revealed that SLC2A1 functions by regulating ferroptosis.

CONCLUSIONS:

In summary, our study not only identifies SLC2A1 as diagnostic biomarker for AKI, but also sheds light on the role of it in AKI progression, providing novel insights for the clinical diagnosis and treatment of AKI.

2021-12-01·Journal of the Egyptian National Cancer Institute

An in vitro cytotoxicity of glufosfamide in HepG2 cells relative to its nonconjugated counterpart

Article

作者: Rashidi, Fatma B ; Mohamed, Amr S ; Abdelhakim, Heba K ; Ahmed, Doaa E ; Arafa, Hossam M M

Abstract:

Background:

Glufosfamide (β-d-glucosylisophosphoramide mustard, GLU) is an alkylating cytotoxic agent in which ifosforamide mustard (IPM) is glycosidically linked to the β-d-glucose molecule. GLU exerted its cytotoxic effect as a targeted chemotherapy. Although, its cytotoxic efficacy in a number of cell lines, there were no experimental or clinical data available on the oncolytic effect of oxazaphosphorine drugs in hepatocellular carcinoma. Therefore, the main objective of the current study is to assess the cytotoxic potential of GLU for the first time in the hepatocellular carcinoma HepG2 cell line model.

Methods:

Cytotoxicity was assayed by the MTT method, and half-maximal inhibitory concentration (IC50) was calculated. Flow cytometric analysis of apoptosis frequencies was measured by using Annexin V/PI double stain, an immunocytochemical assay of caspase-9, visualization of caspase-3, and Bcl2 gene expression were undertaken as apoptotic markers. Mitochondrial membrane potential was measured using the potentiometric dye; JC-1, as a clue for early apoptosis as well as ATP production, was measured by the luciferase-chemiluminescence assay.

Results:

Glufosfamide induced cytotoxicity in HepG2 cells in a concentration- and time-dependent manner. The IC50 values for glufosfamide were significantly lower compared to ifosfamide. The frequency of apoptosis was much higher for glufosfamide than that of ifosfamide. The contents of caspase-9 and caspase-3 were elevated following exposure to GLU more than IFO. The anti-apoptotic Bcl2 gene expression, the mitochondrial membrane potential, and the cellular ATP levels were significantly decreased than in case of ifosfamide.

Conclusions:

The current study reported for the first time cytotoxicity activity of glufosfamide in HepG2 cells in vitro. The obtained results confirmed the higher oncolytic activity of glufosfamide than its aglycone ifosfamide. The generated data warrants further elucidations by in vivo study.

2021-02-01·Thrombosis research3区 · 医学

Possible immune regulation mechanisms for the progression of chronic thromboembolic pulmonary hypertension

3区 · 医学

Article

作者: Liu, Min ; Wang, Ying ; Dong, Xingbei ; Zhong, Jiuchang ; Wan, Jun ; Zhai, Zhenguo ; Yang, Yuanhua ; Guo, Xiaojuan ; Li, Yidan ; Yang, Suqiao ; Li, Jifeng ; Kuang, Tuguang ; Miao, Ran ; Gong, Juanni

PURPOSE:

This study aimed to screen key genes significantly associated with chronic thromboembolic pulmonary hypertension (CTEPH) and predicted suitable drugs for the treatment of CTEPH from the perspective of immune cells.

METHODS:

The dataset GSE130391 was used for this analysis. Differentially expressed genes (DEGs) between the CTEPH and control groups were screened. Abundance of infiltrating immune cells was analyzed and immune-related DEGs were identified. Next, the circular RNA (circRNA)-micro RNA (miRNA)-mRNA network was constructed, followed by functional enrichment analysis. Then, the protein-protein interaction (PPI) network was constructed and drug-gene interactions were predicted. Finally, miRNA and circRNA prediction results were verified by our previously published studies.

RESULTS:

Five key immune cell-related DEGs [CD83 molecule (CD83), complement c5a receptor 1 (C5AR1), atypical chemokine receptor 1 (ACKR1), profilin 2 (PFN2), and solute carrier family 2 member 3 (SLC2A3)] were identified. Several circRNA-miRNA-mRNA interactions were obtained, including circ_0022342miR-503-5pSLC2A3 and circ_0002062miR-92b-3p/miR-92a-3pmannosidase alpha class 2A member 1 (MAN2A1). Immune cell for SLC2A3 was eosinophils and for MAN2A1 was regulatory T cells (Tregs). Additionally, Glufosfamide and Kifunensine might be suitable as candidate drugs for CTEPH treatment.

CONCLUSIONS:

SLC2A3 and MAN2A1 may be important genes for the pathogenesis of CTEPH. Possible immune regulation mechanisms in CTEPH may be circ_0022342miR-503-5pSLC2A3 and circ_0002062miR-92b-3p/miR-92a-3pMAN2A1. These results may be helpful for the diagnosis and treatment of CTEPH from the perspective of immunology.

项与葡膦酰胺相关的新闻（医药）

2026-02-28

·个人图书馆

【原】胰腺癌药物市场的现状与未来

-01-引言胰腺癌，尤其是占主导地位的胰腺导管腺癌，以其侵袭性生物学行为和有限的治疗选择而闻名，其导致的死亡人数与发病率极不相称，这使其成为肿瘤学领域最严峻的挑战之一。胰腺癌大多数病例是外分泌肿瘤（90-95%），主要是发生在导管衬里的胰腺导管腺癌（PDAC）。胰腺神经内分泌肿瘤（PNET）很少见（<5%），起源于产生激素的胰岛细胞。PDAC预后不良（5年生存率约为13%），而PNET与更有利的结果相关（5年生存率约为50%）。这一严峻现实背后，是庞大的未满足临床需求与快速演进的药物研发战场。-02-一、当前治疗标准：化疗为主，靶向与免疫精准突破对于PDAC，手术切除仍是早期局部性疾病的标准治疗，术后需进行辅助化疗。在辅助治疗中，改良的FOLFIRINOX方案因其在疗效与毒性间的平衡，已成为体能状态良好患者的首选。对于无法切除的局部晚期或转移性PDAC，一线标准方案包括FOLFIRINOX、吉西他滨联合白蛋白结合型紫杉醇，以及最新于2024年获得FDA批准的NALIRIFOX方案。NALIRIFOX相比FOLFIRINOX，血液学毒性和神经病变发生率更低，但腹泻发生率更高。尽管化疗是基石，但针对特定基因突变的精准治疗为小部分患者带来了曙光。例如，PARP抑制剂奥拉帕利被批准用于携带胚系BRCA突变、且在一线铂类化疗后未进展的转移性PDAC患者的维持治疗，这类患者约占4-7%。PD-1抑制剂帕博利珠单抗则适用于高度微卫星不稳定或错配修复缺陷的肿瘤（约占1-2%）。此外，针对NRG1基因融合（约占1-3%）的双特异性抗体Zenocutuzumab也于近期获得加速批准。对于pNETs，手术是早期疾病的主要手段，而生长抑素类似物（如奥曲肽和兰瑞肽）则是控制晚期疾病激素相关症状的一线标准疗法。对于进展性疾病，mTOR抑制剂依维莫司、酪氨酸激酶抑制剂舒尼替尼和卡博替尼是获批的系统治疗选择，肽受体放射性核素疗法¹⁷⁷Lu-Dotatate则用于SSTR阳性的胃肠胰神经内分泌肿瘤。-03- 二、新兴疗法管线：靶向治疗与放射性药物引领未来晚期研发管线主要由具有新作用机制的靶向疗法和放射性药物主导。在PDAC领域，多选择性RAS(ON)抑制剂Daraxonrasib是备受瞩目的明星分子，其正在三项III期试验中进行评估，覆盖了经治转移性疾病、术后辅助治疗以及一线治疗等多个场景。该药物已于2025年获得FDA的“优先审评券”和突破性疗法认定。CD73抑制剂Quemliclustat联合化疗正在一线转移性PDAC中进行III期试验（PRISM-1），并于2025年获得孤儿药认定。其他处于晚期研发阶段的药物包括多胺类似物Ivospemin、PRMT5抑制剂Navlimetostat（靶向MTAP缺失肿瘤，约占21%）、细胞毒药物Glufosfamide以及TGF-β2抑制剂Trabedersen等。值得注意的是，GSK-3β抑制剂Elraglusib在一线II期试验中已达到主要终点，MEK抑制剂Atebimetinib也计划于2026年启动全球III期试验。在pNETs领域，两种新型放射性标记的生长抑素类似物¹⁷⁷Lu-Edotreotide和²²⁵Ac-Dotatate正在晚期临床试验中，前者已进入FDA审评阶段。下一代多靶点激酶抑制剂Zanzalintinib也在进行II/III期研究。-04-三、市场格局与未来展望根据Clarivate的预测，胰腺癌药物市场在主要七大市场的销售额在2025年总计约为32亿美元，并预计到2034年将增长至97亿美元，其中PDAC贡献了绝大部分份额。2025年，细胞毒药物主导了PDAC市场，销售额达22亿美元，其中白蛋白结合型紫杉醇以12亿美元领先。而包括PARP抑制剂、PD-1抑制剂和双特异性抗体在内的分子靶向疗法贡献了2.9亿美元，反映了其在特定小人群中的应用。未来市场将发生显著变化。到2034年，RAS抑制剂（主要由Daraxonrasib驱动）预计将成为最畅销的药物类别，销售额达38亿美元，而MEK抑制剂（主要由Atebimetinib驱动）预计将产生15亿美元销售额。得益于其在一线化疗中的广泛应用以及与新兴疗法的联合探索，吉西他滨联合白蛋白结合型紫杉醇的销售额预计将接近20亿美元。pNETs市场预计到2034年将接近10亿美元，其中放射性标记的生长抑素类似物和酪氨酸激酶抑制剂合计贡献约4.6亿美元。-05-结语胰腺癌药物市场正处于一个关键的转型期。尽管当前治疗仍以化疗为支柱，且靶向治疗仅惠及少数患者，但蓬勃发展的研发管线，特别是针对KRAS等关键驱动因子的突破性疗法，预示着治疗范式即将迎来变革。未来十年，市场增长将主要由这些创新疗法驱动，它们有望为这种毁灭性疾病带来更有效、更精准的治疗选择，最终改善患者的生存预后。这场对抗胰腺癌的战争，正在从漫长的僵局转向充满战略进攻的新阶段。参考资料：The pancreatic cancer drug market. Nat Rev Drug Discov. 2026 Feb 20.

优先审批临床3期放射疗法突破性疗法免疫疗法

2026-02-28

·小药说药

胰腺癌药物市场的现状与未来

-01- 引言胰腺癌，尤其是占主导地位的胰腺导管腺癌，以其侵袭性生物学行为和有限的治疗选择而闻名，其导致的死亡人数与发病率极不相称，这使其成为肿瘤学领域最严峻的挑战之一。胰腺癌大多数病例是外分泌肿瘤（90-95%），主要是发生在导管衬里的胰腺导管腺癌（PDAC）。胰腺神经内分泌肿瘤（PNET）很少见（<5%），起源于产生激素的胰岛细胞。PDAC预后不良（5年生存率约为13%），而PNET与更有利的结果相关（5年生存率约为50%）。这一严峻现实背后，是庞大的未满足临床需求与快速演进的药物研发战场。 -02- 一、当前治疗标准：化疗为主，靶向与免疫精准突破对于PDAC，手术切除仍是早期局部性疾病的标准治疗，术后需进行辅助化疗。在辅助治疗中，改良的FOLFIRINOX方案因其在疗效与毒性间的平衡，已成为体能状态良好患者的首选。对于无法切除的局部晚期或转移性PDAC，一线标准方案包括FOLFIRINOX、吉西他滨联合白蛋白结合型紫杉醇，以及最新于2024年获得FDA批准的NALIRIFOX方案。NALIRIFOX相比FOLFIRINOX，血液学毒性和神经病变发生率更低，但腹泻发生率更高。尽管化疗是基石，但针对特定基因突变的精准治疗为小部分患者带来了曙光。例如，PARP抑制剂奥拉帕利被批准用于携带胚系BRCA突变、且在一线铂类化疗后未进展的转移性PDAC患者的维持治疗，这类患者约占4-7%。PD-1抑制剂帕博利珠单抗则适用于高度微卫星不稳定或错配修复缺陷的肿瘤（约占1-2%）。此外，针对NRG1基因融合（约占1-3%）的双特异性抗体Zenocutuzumab也于近期获得加速批准。对于pNETs，手术是早期疾病的主要手段，而生长抑素类似物（如奥曲肽和兰瑞肽）则是控制晚期疾病激素相关症状的一线标准疗法。对于进展性疾病，mTOR抑制剂依维莫司、酪氨酸激酶抑制剂舒尼替尼和卡博替尼是获批的系统治疗选择，肽受体放射性核素疗法¹⁷⁷Lu-Dotatate则用于SSTR阳性的胃肠胰神经内分泌肿瘤。 -03- 二、新兴疗法管线：靶向治疗与放射性药物引领未来晚期研发管线主要由具有新作用机制的靶向疗法和放射性药物主导。在PDAC领域，多选择性RAS(ON)抑制剂Daraxonrasib是备受瞩目的明星分子，其正在三项III期试验中进行评估，覆盖了经治转移性疾病、术后辅助治疗以及一线治疗等多个场景。该药物已于2025年获得FDA的“优先审评券”和突破性疗法认定。 CD73抑制剂Quemliclustat联合化疗正在一线转移性PDAC中进行III期试验（PRISM-1），并于2025年获得孤儿药认定。其他处于晚期研发阶段的药物包括多胺类似物Ivospemin、PRMT5抑制剂Navlimetostat（靶向MTAP缺失肿瘤，约占21%）、细胞毒药物Glufosfamide以及TGF-β2抑制剂Trabedersen等。值得注意的是，GSK-3β抑制剂Elraglusib在一线II期试验中已达到主要终点，MEK抑制剂Atebimetinib也计划于2026年启动全球III期试验。在pNETs领域，两种新型放射性标记的生长抑素类似物¹⁷⁷Lu-Edotreotide和²²⁵Ac-Dotatate正在晚期临床试验中，前者已进入FDA审评阶段。下一代多靶点激酶抑制剂Zanzalintinib也在进行II/III期研究。 -04- 三、市场格局与未来展望根据Clarivate的预测，胰腺癌药物市场在主要七大市场的销售额在2025年总计约为32亿美元，并预计到2034年将增长至97亿美元，其中PDAC贡献了绝大部分份额。2025年，细胞毒药物主导了PDAC市场，销售额达22亿美元，其中白蛋白结合型紫杉醇以12亿美元领先。而包括PARP抑制剂、PD-1抑制剂和双特异性抗体在内的分子靶向疗法贡献了2.9亿美元，反映了其在特定小人群中的应用。未来市场将发生显著变化。到2034年，RAS抑制剂（主要由Daraxonrasib驱动）预计将成为最畅销的药物类别，销售额达38亿美元，而MEK抑制剂（主要由Atebimetinib驱动）预计将产生15亿美元销售额。得益于其在一线化疗中的广泛应用以及与新兴疗法的联合探索，吉西他滨联合白蛋白结合型紫杉醇的销售额预计将接近20亿美元。pNETs市场预计到2034年将接近10亿美元，其中放射性标记的生长抑素类似物和酪氨酸激酶抑制剂合计贡献约4.6亿美元。 -05- 结语胰腺癌药物市场正处于一个关键的转型期。尽管当前治疗仍以化疗为支柱，且靶向治疗仅惠及少数患者，但蓬勃发展的研发管线，特别是针对KRAS等关键驱动因子的突破性疗法，预示着治疗范式即将迎来变革。未来十年，市场增长将主要由这些创新疗法驱动，它们有望为这种毁灭性疾病带来更有效、更精准的治疗选择，最终改善患者的生存预后。这场对抗胰腺癌的战争，正在从漫长的僵局转向充满战略进攻的新阶段。参考资料： The pancreatic cancer drug market. Nat Rev Drug Discov. 2026 Feb 20. 公众号已建立“小药说药专业交流群”微信行业交流群以及读者交流群，扫描下方小编二维码加入，入行业群请主动告知姓名、工作单位和职务。

2026-01-06

·ir.bullfrogai.com

BullFrog AI-Driven Precision Oncology Analytics Identifies 3x Increase in Overall Survivability in Patient Subgroups through Key Biomarkers in Pancreatic Cancer

GAITHERSBURG, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology company using artificial intelligence (“AI”) and machine learning to turn complex biomedical data into actionable insights, highlights the presentation of data derived from the use of the Company’s proprietary platform bfLEAP® with pancreatic cancer trial data to identify an almost three times increase in mean survival from the control to treatment arms. The data will be presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on Jan. 9 at poster session B. The presentation, in collaboration with Eleison Pharmaceuticals and the Moffitt Cancer Center, is titled, “Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma,” and will subsequently appear in the Journal of Clinical Oncology (JCO) supplement corresponding to the symposium. “The glufosfamide case study in pancreatic cancer successfully showcased the utility of our platform to provide drug developers with an end-to-end analytical tool engineered to resolve multimodal biological complexity at scale,” said BullFrog AI Founder and CEO Vin Singh. “Too much time and capital are wasted in drug development traveling down incorrect pathways, ultimately leaving patients without effective treatments. The power of bfLEAP® and bfPREP™ is their ability to give drug developers a clear path forward based on previous data and indicators to focus on key benchmarks, limiting the amount of wasteful spending on less-than-ideal targets.” The study explored data-driven precision-oncology approaches leveraging BullFrog AI’s bfLEAP® and bfPREP™ platforms to analyze complex clinical datasets, uncover biologically meaningful patient clusters, and identify patient subtypes that may demonstrate enhanced response to glufosfamide, an investigational chemotherapeutic agent for pancreatic cancer. In the post-hoc analysis of TH-CR-302, a randomized phase 3 clinical trial evaluating glufosfamide against the best supportive care (BSC), the analysis discovered key biomarkers that influenced an almost threefold increase in mean survival from the control to treatment arms. The research group concluded that ensemble approaches like bfLEAP® can successfully identify patient subgroups within existing glufosfamide clinical trial data. Treatment effect heterogeneity was identified among clusters, identifying possible early predictors of outcomes, and highlighting the effectiveness of data-driven clustering approaches to refine patient stratification and guide the development of personalized treatment strategies. The study was co-authored by Richard Kim, M.D., Service Chief of Medical Gastrointestinal Oncology and Senior Member in the Gastrointestinal Oncology Department at Moffitt Cancer Center, Nikolas Naleid, M.D., Pharm.D., Hematology/Oncology Fellow at Moffitt Cancer Center, Eleison Pharmaceuticals, and BullFrog AI. About BullFrog AI BullFrog AI leverages artificial intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP® platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials. For more information visit BullFrog AI at: https://bullfrogai.com. Safe Harbor Statement This press release contains forward-looking statements. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance, including: our financial performance and projections; our revenue and earnings; and our business prospects and opportunities. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “could,” “will,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential,” or “hopes” or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; our and our partners’ ability to market and sell our offerings and services, including BullFrog Data Networks™; our ability to maintain compliance with Nasdaq listing rules; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. Contact: Investors: CORE IR ir@bullfrogai.com Media: CORE PR pr@bullfrogai.com Released January 6, 2026

ASCO会议临床3期

100 项与葡膦酰胺相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	葡膦酰胺	-	DB06177

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性胰腺癌	临床3期	美国	Threshold Pharmaceuticals, Inc.	2004-09-01
转移性胰腺癌	临床3期	阿根廷	Threshold Pharmaceuticals, Inc.	2004-09-01
转移性胰腺癌	临床3期	巴西	Threshold Pharmaceuticals, Inc.	2004-09-01
转移性胰腺癌	临床3期	保加利亚	Threshold Pharmaceuticals, Inc.	2004-09-01
转移性胰腺癌	临床3期	捷克	Threshold Pharmaceuticals, Inc.	2004-09-01
转移性胰腺癌	临床3期	匈牙利	Threshold Pharmaceuticals, Inc.	2004-09-01
转移性胰腺癌	临床3期	印度	Threshold Pharmaceuticals, Inc.	2004-09-01
转移性胰腺癌	临床3期	墨西哥	Threshold Pharmaceuticals, Inc.	2004-09-01
转移性胰腺癌	临床3期	罗马尼亚	Threshold Pharmaceuticals, Inc.	2004-09-01
转移性胰腺癌	临床3期	俄罗斯	Threshold Pharmaceuticals, Inc.	2004-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00442598 (CTgov)	临床2期	卵巢癌 \| 卵巢上皮癌	17	Glufosfamide (Glufosfamide q21 Days)	窪醖淵獵糧艱觸鬱鹹壓 = 鏇襯鑰鏇壓鬱醖蓋壓範淵壓艱選繭淵壓膚艱積 (顧願糧艱鹹鹽憲壓觸鹽, 餘衊願鬱繭積鏇窪衊願 ~ 鹹壓蓋糧衊鹹鑰築衊顧) 更多	-	2015-03-10
NCT00442598 (CTgov)	临床2期	卵巢癌 \| 卵巢上皮癌	17	Glufosfamide (Glufosfamide q7 Days Low)	窪醖淵獵糧艱觸鬱鹹壓 = 觸憲網築憲蓋築鬱選觸淵壓艱選繭淵壓膚艱積 (顧願糧艱鹹鹽憲壓觸鹽, 遞積鹹繭觸憲齋繭顧淵 ~ 選獵築鹹鏇蓋膚積襯遞) 更多	-	2015-03-10
NCT00441467 (CTgov)	临床2期	局部晚期软组织肉瘤 \| 软组织肉瘤	22	Glufosfamide	構網選衊襯觸鬱鑰製簾 = 網憲製鏇餘憲壓壓壓廠積憲築糧鑰膚鏇餘鹽蓋 (齋積齋鹽鹽鏇積鹹鬱構, 鬱遞鬱獵積廠蓋夢淵繭 ~ 齋網衊糧鏇襯醖範醖積) 更多	-	2015-03-02
ASCO2007	临床2期	胰腺腺癌	29	Glufosfamide 4500 mg/m2 + Gemcitabine 1000 mg/m2	窪鏇艱襯糧鬱蓋衊築鹽(廠淵憲蓋獵衊鹽膚餘廠) = 齋窪窪願觸廠製廠膚淵襯鹹憲積鏇廠衊製壓廠 (獵構壓鹹簾築鑰鹹壓觸, 8 ~ 41) 更多	-	2007-06-20
ASCO2006	临床1期	晚期恶性实体瘤	-	Glufosfamide	積糧夢廠選鹹鹽範醖廠(獵鬱壓蓋膚壓蓋窪鹹蓋) = 膚鑰鏇鬱網願遞衊醖憲顧餘醖範齋顧選觸鬱醖 (鹹積網鹽襯遞壓鬱積築 )	-	2006-06-20
ASCO2004	临床2期	晚期乳腺癌	22	Glufosfamide	繭餘醖網鹽壓鏇積憲齋(鹹夢觸製襯憲襯憲壓夢) = 鹹網鑰鹹網蓋範網構窪壓網壓襯鹽構淵壓選範 (選製壓衊夢構壓製糧醖 ) 更多	-	2004-07-15
Pubmed \| Eur J Cancer	临床2期	晚期非小细胞肺癌二线	39	Glufosfamide	範鹽鹹襯鏇遞製鹹壓積(築觸淵窪餘構鹹糧膚齋) = 夢積製選壓夢觸願觸廠觸獵齋鹹製鏇膚鹹簾築 (窪醖淵壓壓醖膚醖願製, 4.2 ~ 7.9) 更多	-	2004-03-01
Pubmed \| Eur J Cancer	临床2期	胰腺癌一线	35	Glufosfamide	艱鹽淵窪築願繭簾繭簾(遞齋糧簾鑰觸憲鏇窪鏇) = recorded in 5 patients 遞鑰構鹽膚積襯夢範夢 (願窪積窪構鬱鬱繭繭蓋 ) 更多	不佳	2003-11-01